Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 75

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Colorectal cancer metastatic

Not recruiting

Study of SCO-101 with FOLFIRI for Patients with Metastatic Colorectal Cancer Resistant to FOLFIRI

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Disodium Folinate
  • Sponsor:Scandion Oncology A/S

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Malignant peritoneal neoplasm+2

Not recruiting

Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oregovomab
  • Sponsor:Canariabio Inc.

Cystic fibrosis

Not recruiting

Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Adalimumab for Children with Ulcerative Colitis Who Completed Previous Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cystic fibrosis

Not recruiting

Study of anakinra safety and effectiveness given by injection under the skin in patients with cystic fibrosis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Crohn's disease

Not recruiting

Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Colorectal cancer metastatic+14

Not recruiting

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Colitis ulcerative

Not recruiting

Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Rifamycin Sodium
  • Sponsor:Cosmo Technologies Limited

Cystic fibrosis gastrointestinal disease

Not recruiting

Study on the Acceptability of Pancreas Powder for Patients with Cystic Fibrosis and Pancreatic Exocrine Insufficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pancreas Powder
  • Sponsor:MEDA Pharma GmbH & Co. KG

Colorectal cancer+2

Not recruiting

Study of E7386 and Pembrolizumab for Patients with Previously Treated Colorectal Cancer, Melanoma, or Hepatocellular Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

Colorectal cancer+6

Not recruiting

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Incb099280
  • Sponsor:Incyte Corp.

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.